SCHEMBL35010

SCHEMBL35010

Nc1c(C(=O)c2cccc(O)c2)cccc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 6/20 0.48
HSD17B2 P37059 4/20 0.48
PARP1 P09874 1/20 0.45
FASN P49327 1/20 0.44
DYRK1A Q13627 4/20 0.43
CLK1 P49759 3/20 0.43
DYRK1B Q9Y463 3/20 0.43
P2RX1 P51575 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA6 P23280 1/20 0.42
CA9 Q16790 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PTGS1 P23219 1/20 0.41
KCNK3 O14649 1/20 0.41
KCNK9 Q9NPC2 1/20 0.41
STS P08842 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3507106 0.85 MAPT (0.50) PARP1ALDH1A1PTGS1KCNK3KCNK9
SCHEMBL1124058 0.84 MAPT (0.53) ALDH1A1PTGS1KCNK3KCNK9
SCHEMBL15608407 0.84 POLB (0.54) PARP1ALDH1A1PTGS1KCNK3KCNK9
SCHEMBL3509598 0.81 MAPT (0.54) PARP1KDM4EALDH1A1STS
SCHEMBL35142 0.77 HSD17B1 (0.49) HSD17B1HSD17B2PARP1FASNDYRK1A
SCHEMBL4014144 0.77 PARP1 (0.49) HSD17B1HSD17B2PARP1FASNDYRK1A
SCHEMBL1125082 0.76 MAPT (0.48) PARP1ALDH1A1STS
SCHEMBL28620541 0.75 FASN (0.53) HSD17B1HSD17B2PARP1FASNDYRK1A
SCHEMBL8080314 0.74 MAPT (0.67) HSD17B1HSD17B2PARP1FASNDYRK1A
SCHEMBL158167 0.74 G6PD (0.55) KDM4EALDH1A1PTGS1KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590948-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS Wyeth LLC (US) 2013-05-15 EP disclosed
WO-2012004748-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS WYETH LLC (US) 2012-01-12 WO disclosed
US-20120010205-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS WYETH LLC (US) 2012-01-12 US disclosed
EP-2284157-A1 Quinolines useful in treating cardiovascular disease Wyeth (US) 2011-02-16 EP disclosed
US-7576215-B2 Quinolines and pharmaceutical compositions thereof WYETH (US) 2009-08-18 US disclosed
CN-1914173-A Quinolines useful in treating cardiovascular disease WYETH CORP (US) 2007-02-14 CN disclosed
EP-1692111-A2 QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE Wyeth, A Corporation of the State of Delaware (US) 2006-08-23 EP disclosed
WO-2005058834-A2 QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE WYETH (US) 2005-06-30 WO disclosed
US-20050131014-A1 Quinolines useful in treating cardiovascular disease WYETH (US) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131014-A1 Quinolines useful in treating cardiovascular disease NR1H2, NR1H3, SREBF1 HSD17B1 150/4885HSD17B2 240/4885PARP1 1858/4885
US-20120010205-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS NR1H2, NR1H3, NR1H4 HSD17B1 69/4885HSD17B2 88/4885PARP1 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.